Nucala (mepolizumab) / GSK - LARVOL DELTA

Fasenra, Nucala equally effective, safe in EGPA: Real-world study (ANCA Vasculitis News) - P=NA | N=176 | "The results showed that after three months of treatment, complete or partial responses were achieved by a similar proportion of patients treated with Nucala or Fasenra (45.4% vs. 51.1%). The number of patients achieving a complete response increased over time with both medications. However, after one year, the complete response rate was significantly higher in the Fasenra group than among those on Nucala (48.1% vs. 32.4%)...After achieving complete response, five Nucala-treated patients and four Fasenra-treated patients relapsed, the data showed...In terms of safety, there were no significant group differences in the proportions of patients who discontinued treatment — 10% with Nucala and 18% with Fasenra — and who reported adverse events, as done by 12.5% on Nucala and 18% on Fasnra."

Real-world • Eosinophilic Granulomatosis With Polyangiitis

Racial and Ethnic Disparities in Biologic Prescriptions for CRSwNP in the United States (COSM 2025) - "A higher proportion of NHB patients were started on any FDA approved biologic for CRSwNP compared to NHW patients (risk difference [RD] 1.2%, p=0.0008), as well as individual biologics: omalizumab (RD 0.4%, p=0.011), dupilumab (RD 0.9%, p=0.0028), mepolizumab (RD 0.3%, p=0.0317). Retrospective analysis of claims based data for CRSwNP management found that NHB patients were more likely, and Hispanic patients were less likely, to be prescribed biologics compared to NHW patients."

Asthma • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Dermatitis • Dermatology • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis • Urticaria

Systematic review of measured biomarker changes after biologic treatments for CRSwNP (COSM 2025) - " Of 51 included studies, breakdown by biologic was: Dupilumab- 26, Omalizumab- 8, Mepolizumab- 6, Benralizumab- 8, Resilizumab-1, and other-2. Current literature studying biologics in CRSwNP have predominantly focused on only a select few biomarkers known to be key mediators of type 2 inflammation. Systemic top 3- IgE (19), Eosinophils (37) and ECP (8). Nasal top 3- Eosinophils (10), IgE (7), ECP (7)."

Biomarker • Review • Chronic Rhinosinusitis With Nasal Polyps • Eosinophilia • Inflammation

Biologics and acute rhinosinusitis: A protective effect (COSM 2025) - "Objective: To assess whether biologic therapies (dupilumab, mepolizumab, and omalizumab) that are approved for chronic sinusitis with nasal polyps (CRSwNP) exhibit a protective effect on sinonasal health even in patients without CRSwNP. Dupilumab and mepolizumab appear to reduce ABRS episodes in patients without CRSwNP, suggesting a protective effect on sinonasal health. These findings highlight the potential use of biologics in managing patients with refractory recurrent acute sinusitis despite surgery. Further studies are needed to confirm these effects and to evaluate risks associated with long-term biologic use in non-CRSwNP populations."

Allergic Rhinitis • Asthma • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Dermatitis • Dermatology • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Rheumatic adverse events in biologics for CRS (COSM 2025) - " 21 studies met the final inclusion criteria, totalling 3,434 patients of which 2,763 (80%) received either dupilumab (n=2,257; 82%), mepolizumab (n=372; 13%), or omalizumab (n=134; 5%) for treatment of CRSwNP. Biologic therapy increases the risk of rheumatic AEs in CRSwNP patients by over two-fold. Healthcare providers should remain vigilant in monitoring rheumatic AEs and apply appropriate management strategies on a case-by-case basis."

Adverse events • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammatory Arthritis • Lupus • Musculoskeletal Diseases • Musculoskeletal Pain • Nasal Polyps • Orthopedics • Otorhinolaryngology • Pain • Respiratory Diseases • Sinusitis

Efficacy of Biologic Agents in Management of Pediatric Asthma (PAS 2025) - "Control of severe asthma has always been a challenge, and the advent of biologic therapy (omalizumab, mepolizumab, dupilumab, benralizumab, and tezepelumab) has revolutionized the treatment of this category of asthma. These factors will also be assessed for the year following initiation for evaluation of outcomes. Outcomes pre and post-biologic initiation will be compared using dependent sample t-testing, conducted with IBM SPSS."

Clinical • Asthma • Immunology • Pediatrics • Respiratory Diseases • IL4 • IL5 • TSLP

Blue Cross Blue Shield now requires prior approval for severe asthma drugs in some states (Yahoo News) - "Patients in five states who have severe asthma and are covered by Blue Cross Blue Shield are facing a new obstacle to getting treatment...On Tuesday, BCBS began mandating that severe asthma patients self-administer their drugs at home, unless their provider gets prior approval from the insurance company....The patients affected are those covered in Illinois, Texas, Oklahoma, New Mexico, and Montana, but not those with Medicare or Medicaid, the insurance giant says. Those five states are included in a combined BCBS plan which is owned by Health Care Service Corporation...Given as injections, the treatments in question are Fasenra (benralizumab), Tezspire (tezepelumab), Nucala (mepolizumab) and Xolair (omalizumab). All belong to a class of drugs known as biologics."

Commercial • Asthma • Immunology

Circulating Mast Cell Progenitors Are Depleted by Benralizumab in Severe Asthma. (PubMed, Allergy) - No abstract available

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Comparative effectiveness of dupilumab versus mepolizumab and benralizumab in asthma: a multinational retrospective cohort study. (PubMed, J Allergy Clin Immunol Pract) - "Dupilumab was associated with a decreased risk of asthma exacerbations compared to both mepolizumab and benralizumab among patients with asthma. Further research incorporating comprehensive biomarker data is needed to optimize biologic selection."

HEOR • Journal • Retrospective data • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Mepolizumab in severe uncontrolled CRSwNP: a real-life multicentre study in Northeast Italy. (PubMed, Rhinology) - "Mepolizumab is effective in improving nasal obstruction and the sense of smell in patients with severe uncontrolled CRSwNP, based on both patient- and physician derived outcome measures."

Journal • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Pain • Pulmonary Disease • Respiratory Diseases • Sinusitis

Early Intervention with Mepolizumab, Corticosteroids, and Intravenous Immunoglobulin for Dupilumab-Triggered Eosinophilic Granulomatosis with Polyangiitis: A Case Report. (PubMed, J Asthma Allergy) - "This case emphasizes the importance of monitoring preexisting MPO-ANCA and blood eosinophils before and during dupilumab therapy. Early intervention with mepolizumab combined with conventional therapy is considered an optimal treatment strategy for dupilumab-triggered EGPA."

Journal • Allergic Bronchopulmonary Aspergillosis • Asthma • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Musculoskeletal Pain • Otorhinolaryngology • Pain • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Sinusitis • Vasculitis • FIP1L1 • IL5 • MPO • PDGFRA

Effectiveness of tezepelumab in preventing relapse of eosinophilic granulomatosis with polyangiitis: A case report. (PubMed, Respir Investig) - "A 54-year-old woman diagnosed with eosinophilic granulomatosis accompanied by polyangiitis (EGPA) was in remission with prednisolone (PSL) and mepolizumab treatment. Consequently, the treatment with benralizumab was changed to tezepelumab, after which her symptoms immediately improved and her ANCA levels decreased, enabling reduction in the PSL dosage. This case highlights the potential of tezepelumab to reduce ANCA levels in EGPA-related severe asthma."

Journal • Asthma • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Langerhans Cell Histiocytosis • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Vasculitis

A one year, single centre, prospective study on EGPA patients treated with Mepolizumab (EAACI 2025) - No abstract available

Clinical • Late-breaking abstract • Immunology

Mepolizumab provides sustained clinical benefits in patients with severe asthma regardless of age of asthma onset: Real-world data from the REALITI-A study at 2 years (EAACI 2025) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world evidence • Immunology

Mepolizumab's Safety and Efficacy in Children and Adolescents with Severe Eosinophilic Asthma: A Real-World Perspective (EAACI 2025) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world evidence • Immunology

TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH) (EAACI 2025) - No abstract available

Clinical • Late-breaking abstract • Immunology

Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma Independent of Baseline Blood Eosinophil Count in the Real World: Results from REALITI-A at 2 Years (EAACI 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology

Redefining STAT5B N642H Gain of function Mutation: Unique Phenotypic Features and First Successful Mepolizumab Treatment in a Pediatric Case (EAACI 2025) - No abstract available

Clinical • Immunology • STAT5B

Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment (EAACI 2025) - No abstract available

Clinical • Immunology

Mepolizumab as game changer in a case of severe occupational asthma with rhinitis and contact dermatitis (EAACI 2025) - No abstract available

Clinical • Dermatitis • Immunology • Inflammation

Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma, Independent of Baseline IgE and FeNO in the Real World: 2-Year Results from REALITI-A (EAACI 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology

Decrease in Eosinophil-Derived-Neurotoxin upon mepolizumab is associated with asthma improvement (EAACI 2025) - No abstract available

Immunology

Real-life experience in eosinophilic granulomatosis with polyangiitis (EGPA) after 12 months with mepolizumab 300mg in specialized autoimmune and asthma units in an Universitary Hospital (EAACI 2025) - No abstract available

Clinical • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Vasculitis

Nasal polyp CD62Llow eosinophils as a prognostic biomarker of chronic rhinosinusitis with nasal polyp severity and predictive biomarker of mepolizumab and dupilumab response (EAACI 2025) - No abstract available

Biomarker • Allergy • Immunology

REALITI-N: First Ambidirectional Cohort Study Evaluating Real-World Mepolizumab Use in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (EAACI 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology